Phaseline

Companies › Ascidian Therapeutics

Ascidian Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Aug 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ACDN-01
AAV-based vector carrying DNA construct encoding ABCA4 RNA exon editor
ABCA4Phase 1Stargardt DiseaseAug 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06467344ACDN-01Phase 1Stargardt DiseaseOphthalmologyAug 2030

Targets

ABCA4 (1)

Companies with the same targets

VeonGen Therapeutics AAVantgarde Bio Srl

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.